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Summary
Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from 
colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery 
compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.
Methods This parallel-group study reports the trial’s ﬁ nal data for progression-free survival for a protocol unspeciﬁ ed 
interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal 
cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles 
after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were 
centrally randomised by minimisation, adjusting for centre and risk score. The primary objective was to detect a 
hazard ratio (HR) of 0·71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses 
were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, 
number NCT00006479.
Findings In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1–6) 
preoperative cycles and 115 (63%) patients received a median six (1–8) postoperative cycles. 152 (84%) patients were 
resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7·3% (from 
28·1% [95·66% CI 21·3–35·5] to 35·4% [28·1–42·7]; HR 0·79 [0·62–1·02]; p=0·058) in randomised patients; 8·1% 
(from 28·1% [21·2–36·6] to 36·2% [28·7–43·8]; HR 0·77 [0·60–1·00]; p=0·041) in eligible patients; and 9·2% (from 
33·2% [25·3–41·2] to 42·4% [34·0–50·5]; HR 0·73 [0·55–0·97]; p=0·025) in patients undergoing resection. 
139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative 
complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0·04). 
After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group.
Interpretation Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the 
risk of events of progression-free survival in eligible and resected patients. 
Funding Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer 
Institute, Sanoﬁ -Aventis.
Introduction
Liver metastases are detected in 40–50% of the nearly one 
million patients who are diagnosed with colorectal cancer 
worldwide every year. When surgical resection of these 
metastases is possible, 5-year survival approaches 35%.1 
However, relapse is common and occurs in 75% of 
patients.2
Chemotherapy and surgery combined can reduce the 
risk of relapse. Preoperative chemotherapy potentially 
allows surgery on small tumours that have become 
smaller after preoperative chemotherapy (or in response 
to chemotherapy).3 This method also allows the 
responsiveness of these liver metastases to chemotherapy 
to be assessed, and thus provides guidance about 
whether chemotherapy should be given after the 
resection of metastases. Postoperative chemotherapy 
should theoretically be eﬀ ective in dormant cancer cells 
in the remnant liver. It improves the outcome of patients 
with stage III colon cancers4 and therefore might also be 
eﬀ ective in stage IV disease after surgery.
Previous phase III trials comparing combined 
treatment to surgery alone did not recruit the targeted 
number of patients and thus did not have suﬃ  cient 
statistical power.5–9 However, these trials showed some 
beneﬁ t of postoperative chemotherapy based on 
ﬂ uorouracil combined with surgery. Some trials used 
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intrahepatic arterial infusion and others intravenous 
chemotherapy. Consequently, a varied pattern of practice 
has evolved.
Although surgical resection alone is still regarded as 
the standard of care, many patients are given combined 
treatment. Others receive chemotherapy alone and are 
not referred to liver surgeons, even though their hepatic 
metastases are resectable. Thus, there remains a need for 
clear evidence for whether combined treatment with 
chemotherapy is better than surgery alone in patients 
with resectable liver metastases from colorectal cancer.
The present European Intergroup trial aimed to compare 
perioperative chemotherapy—ie, before and after 
surgery—with surgery alone in patients with one to four 
hepatic colorectal cancer metastases that are considered to 
be resectable on imaging. The trial design did not attempt 
to assess preoperative versus postoperative chemotherapy. 
Methods
Patients
We recruited 364 patients from 78 hospitals (in Australia, 
Austria, Belgium, France, Germany, Hong Kong, Italy, 
Norway, Sweden, Netherlands, UK) between Oct 10, 
2000, and July 5, 2004. To be eligible for enrolment, 
patients had to be aged between 18 and 80 years with a 
WHO performance status of 2 or less, histologically 
proven colorectal cancer, one to four liver metastases that 
were potentially resectable, and no detectable extrahepatic 
tumour. The primary tumour had to be either already 
resected (R0 resection) or judged to be resectable (in case 
of synchronous metastases) by the multidisciplinary 
team at the treating hospital. Patients with previous 
chemotherapy with oxaliplatin were excluded. We 
excluded those with any history of cancer in the past 
10 years (except non-melanoma skin carcinoma or in-situ 
cervix cancer), major hepatic insuﬃ  ciency, an absolute 
neutrophil count less than 1·5×10⁹/L, platelet counts less 
than 100×10⁹/L, serum creatinine more than twice the 
upper limit of normal, grade of common toxicity criteria10 
more than 1 for peripheral neuropathy, uncontrolled 
congestive heart failure, angina pectoris, hypertension, 
arrhythmia, history of signiﬁ cant neurological or 
psychiatric disorders, or active infection. Pregnant or 
breastfeeding women were also excluded.
Clinical examination, chest radiography, abdomino-
pelvic CT scan with contrast medium (spiral CT was 
recommended) or MRI, electrocardiogram, and standard 
laboratory work-up were undertaken within 14 days of 
study entry. The trial was approved by the medical ethics 
committees of all participating centres. Written informed 
consent was obtained from all patients before 
randomisation.
Procedures
Randomisation was done at the European Organisation 
for Research and Treatment of Cancer (EORTC) 
Headquarters in Brussels with the minimisation 
technique,11 and was stratiﬁ ed for centre, previous 
adjuvant chemotherapy to primary surgery for colorectal 
cancer, and a risk score derived from Nordlinger and 
colleagues.2
We chose the FOLFOX4 regimen for the study, since 
patients with metastatic colorectal cancer assigned to 
this treatment have previously shown a response rate 
above 50% and an increase in progression-free survival.12 
Details of this regimen have been previously reported.13 
Patients were randomly assigned to either six cycles of 
FOLFOX4 before and six cycles after surgery 
(perioperative chemotherapy group), which were given 
unless the tumour progressed during preoperative 
chemotherapy, or to surgery alone. Each cycle of 
chemotherapy lasted 14 days, with the subsequent cycle 
to start on day 15.12
In both groups, the study treatment had to start within 
3 weeks of randomisation. In the perioperative 
chemotherapy group, liver resection was done 2–5 weeks 
after the last administration of preoperative chemotherapy, 
and whenever patients had completely recovered from 
side-eﬀ ects of chemotherapy with a WHO performance 
status of 0 or 1, and adequate liver function.
Surgical exploration consisted of inspection of the 
peritoneal cavity to exclude extrahepatic involvement, and 
histological examination of frozen sections of any sus-
picious lesion. We used intraoperative ultrasonography to 
detect and localise all hepatic metastases. The type and 
extent of curative liver resection (wedge resection, or mono-
segmentectomy or plurisegmentectomy) was decided by 
the surgeon with the multidisciplinary team at the treating 
hospital at the time of randomisation, but was modiﬁ ed if 
previously undetected deposits were discovered, or if the 
tumour was larger than was expected.
Clinical and neurological examination and assessment 
of haematology, biochemistry, and toxic eﬀ ects12 were 
undertaken before each chemotherapy cycle, and up to 30 
days after treatment. An abdomino-pelvic CT scan (or 
MRI) was done after the ﬁ rst three chemotherapy cycles, 
and before and after liver surgery. The tumour response 
in the liver was assessed by contrast CT scan after three 
and six cycles of preoperative chemotherapy and was 
scored according to response criteria in solid tumour 
(RECIST)14 by the local radiologist; no con ﬁ rmation of 
response was needed. Chest radiography, abdominal 
ultrasound or CT scan, and carcinoembryonic antigen 
concentrations were assessed every 3 months for 2 years 
after the end of treatment and every 6 months thereafter. 
Recurrence was diagnosed by imaging, cytology, or 
histology. When deemed unresectable or after recurrence, 
patients were treated at the physician’s discretion. 
The primary trial endpoint was progression-free survival, 
counted from randomisation to the date of either pro-
gressive or recurrent disease, surgery if metastases were 
deemed not resectable, or death of any cause. To address 
the lead-time bias that was inherent to the design, the event 
time to have occurred at 10 weeks was assigned in both 
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treatment groups in the following circumstances: any 
patient who was operated upon but in whom the tumour 
was not actually resectable, any patient whose tumour was 
resected but recurred within week 1 and 20, or those who 
died between week 1 and 20 of follow-up. Week 10 was 
chosen as being in the middle of these 20 weeks.
The study was planned to detect a 40% increase in 
median progression-free survival, or equivalently an 
increase of the 3-year progression-free survival 
from 21·0% to 32·8%, in all patients randomly assigned 
to perioperative chemotherapy (hazard ratio [HR]=0·714) 
with 80% power at a two-sided 5% signiﬁ cance level, 
requiring 278 events. The trial was expected to provide 
this number of events after 6·5 years. However, at 
6·5 years after trial start (Sept 20, 2006) the events had 
not accumulated at the pace anticipated, but the pressure 
from the medical community to have the trial results 
disclosed was very strong. Therefore, a stopping boundary 
for eﬃ  cacy was implemented (on a gamma family alpha 
spending function with parameter γ=–4).15 An interim 
analysis was then undertaken in November, 2006, (at 
235 events) and shown only to the EORTC independent 
data monitoring committee, who recommended to 
release updated results for the American Society of 
Clinical Oncology (ASCO) meeting in June, 2007, since 
the stopping boundary had been reached. The results 
were thus updated in March, 2007, for the ASCO 
late-breaking abstracts deadline (254 events, 4-year 
median follow-up) and presented at the two-sided 
0·0434 signiﬁ cance level because of the interim analysis.
Statistical analysis
Rates of progression-free survival were estimated by the 
Kaplan-Meier method16 and compared by the logrank test.17 
Eﬀ ects are summarised by the HR and 95·66% CI. We 
used adjusted CIs for all analyses (adjusting for the interim 
analysis), which were set as 95·66% CIs, since the type I 
error rate was α=0·0434. Toxic eﬀ ects and compliance rates 
were compared by the χ² test. In all analyses, patients 
stayed assigned to the group that they had been randomly 
allocated to. The primary analysis was done in all 
randomised patients. Sensitivity analyses (not 
protocol-speciﬁ ed but decided before data analysis) were 
undertaken both in all eligible patients and all those with 
resectable liver metastases. Inference about overall survival 
is deferred until longer follow-up becomes available.
The trial is registered with ClinicalTrials.gov, number 
NCT00006479.
Role of the funding source
The study design, management, data analysis, and data 
interpretation were done at the EORTC headquarters 
(Brussels, Belgium) independently of any commercial 
interest and from all funding bodies. BN and LC had full 
access to all the data in the study. The corresponding 
author had ﬁ nal responsibility for the decision to submit 
for publication. 
64 died 75 died
364 patients randomly assigned
159 were operated
         155 had received chemotherapy
              4 had not received chemotherapy
115 received postoperative
chemotherapy
123 events of progression-free
survival:
22 not operated
7 not resected
49 liver
3 primary
5 regional
23 lung/pleura
9 other site
3 death
2 unspeciﬁed
8 did not have tumour resection
7 more extensive disease
1 liver damage
36 not given postoperative
chemotherapy
9 refusal
8 perioperative complications
6 toxic eﬀects from
preoperative chemotherapy
5 disease progression
1 no remaining disease
at survey
7 unknown
22 were not operated
   1 unkown
8 were not operated
4 unkown
182 allocated to perioperative
therapy
171 eligible
  11 ineligible
182 allocated to surgery only
171 eligible
  11 ineligible
170 were operated
18 did not have tumour resection
      because of more extensive
      disease
152 had tumour resection151 had tumour resection
        148 had received chemotherapy
              3 had not received chemotherapy
131 events of progression-free
survival:
8 not operated
18 not resected
60 liver
2 primary
6 regional lymph nodes
23 lung/pleura
6 other site
6 death
11 did not receive preoperative
      chemotherapy
       7 eligible
       4 ineligible
171 received preoperative
        chemotherapy
1 received preoperative
   chemotherapy
Figure 1: Trial proﬁ le
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Results
Figure 1 shows the trial proﬁ le. 364 patients were 
enrolled, 182 in each group. No log was kept of the 
number of patients who were screened for eligibility. 
Patient and tumour characteristics were much the same 
between the two groups at baseline (table 1). 11 patients 
in each group were ineligible. The reasons for 
ineligibility were more advanced disease than was 
allowed by the protocol (ﬁ ve in perioperative 
chemotherapy group and six in surgery group), primary 
liver cancer (one in both groups), no data (two in 
perioperative chemotherapy group and three in surgery 
group), second cancer (one in surgery group with colon 
cancer), late informed consent (one in perioperative 
chemotherapy group), high serum creatinine (one in 
perioperative chemotherapy group), and resection of 
primary less than 14 days of randomisation (one in 
perioperative chemotherapy group).
In the chemotherapy group, 143 (79%) patients 
completed the planned six cycles of preoperative 
chemotherapy, and 11 (6%) of 182 did not start treatment 
(four ineligible patients and seven eligible patients: four 
who refused, one with colostomy requiring immediate 
surgery, one with alcohol abuse, and one with previous 
raltitrexed treatment).
Table 2 shows compliance, treatment tolerance, and 
treatment response in the perioperative chemotherapy 
group, and table 3 the toxic eﬀ ects. We recorded no deaths 
due to toxic eﬀ ects. Partial or complete response (according 
to RECIST) was recorded in more than two-ﬁ fths of 
patients and the total lesion diameter was reduced by about 
a quarter after chemotherapy (table 2). 12 (7%) patients 
progressed during chemotherapy: eight after 3–4 cycles 
(three of whom underwent subsequent resection) and four 
after six cycles (one resected). Of the eight patients who 
could not undergo resection, unresectability was due to 
appearance of new lesions in four. None of these patients 
started the postoperative protocol chemotherapy. Apart 
from one patient randomly assigned to surgery alone who 
received the whole perioperative chemotherapy at his 
request, none of the patients in the surgery group received 
chemotherapy before recurrence.
Surgery according to the protocol was undertaken at a 
median of 16·6 (range 0·1–30) weeks in the perioperative 
chemotherapy group and 2 (0·1–16) weeks in the surgery 
alone group. Surgery was done in a median of 4·1 
(2·0–16·4) weeks after the last administration of 
preoperative chemotherapy. More patients received the 
operation in the surgery group than in the perioperative 
chemotherapy group (table 4). In both groups, a similar 
number of patients received potentially curative resection 
(table 4). The most frequent reason for non-resectability 
was disease that was more advanced than was expected 
(table 4). In one patient, resection was not done because 
of macroscopic liver damage, which was most probably 
related to chemotherapy. Reversible postoperative 
complications occurred more often after chemotherapy 
PeriOpCT group (N=182) Surgery group (N=182) Total (N=364)
Age (years)
Median (IQR) 62 (29–79) 64 (25–78) 63 (25–79)
Mean (SD) 60·7 (9·35) 62·4 (9·63) 61·6 (9·5)
Sex
Men 127 (70%) 114 (63%) 241 (66%)
Women 54 (30%) 65 (36%) 119 (33%)
No data documentation 
(ineligible)
1 (1%) 3 (2%) 4 (1%)
WHO performance status
0 136 (75%) 150 (82%) 286 (79%)
1 44 (24%) 31 (17%) 75 (21%)
2 2 (1%) 1 (1%) 3 (1%)
Number of liver metastases
1 92* (51%) 95 (52%) 188 (52%)
2 49 (27%) 49 (27%) 94 (26%)
3 27 (15%) 27 (15%) 50 (14%)
1–3 (exact number unknown) 2 (1%) 2 (1%) 4 (1%)
4 12 (7%) 14 (8%) 26 (7%)
>4 (ineligible) 0 2 (1) 2 (1%)
Synchronicity of liver metastases
Metachronous metastases 121 (66%) 115 (63%) 236 (65%)
Synchronous metastases 61 (34%) 67 (37%) 128 (35%)
Time from diagnosis of primary to diagnosis of liver metastases (years)
<2 133 (73%) 139 (76%) 272 (75%)
≥2 49 (27%) 43 (24%) 92 (25%)
T category of the primary cancer
T1 3 (2%) 2 (1%) 5 (1%)
T2 28 (15%) 26 (14%) 54 (15%)
T3 124 (68%) 129 (71%) 253 (70%)
T4 27 (15%) 21 (12%) 48 (13%)
TX 0 4 (2%) 4 (1%)
Lymphatic spread of the primary cancer
N0 81 (45%) 72 (40%) 153 (42%)
N1 69 (38%) 67 (37%) 136 (37%)
N2 31 (17%) 37 (20%) 68 (19%)
NX 1 (1%) 6 (3%) 7 (2%)
Location of primary cancer
Colon 95 (52%) 107 (59%) 202 (56%)
Rectum 84 (46%) 68 (37%) 152 (42%)
Multiple 1 (1%) 3 (2%) 4 (1%)
Unknown 2 (1%) 4 (2%) 6 (2%)
Previous adjuvant chemotherapy for primary cancer
No 104 (57%) 106 (58%) 210 (58%)
Yes (without oxaliplatin) 78 (43%) 76 (42%) 154 (42%)
Plasma CEA at diagnosis, if liver metastases (ng/mL)
≤5·0 66 (36%) 68 (37%) 134 (37%)
5·1–30·0 55 (30%) 60 (33%) 115 (32%)
>30 61 (34%) 54 (30%) 115 (312%)
Data are number (%) unless otherwise indicated. PeriOpCT=perioperative chemotherapy with 5-ﬂ uorouracil/
leucovorin and oxaliplatin. CEA=carcinoembryonic antigen. *One patient was randomised too early and was found to 
have seven metastases on a later CT scan, and thus was ineligible.
Table 1: Baseline characteristics
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than after surgery alone (p=0·04; table 3). After surgery 
we recorded two deaths in the surgery alone group and 
one in the perioperative chemotherapy group. Further 
results regarding the translational research and pathology 
will be presented elsewhere.
115 (63%) patients started postoperative protocol 
chemo therapy, of whom 80 (70%) received six cycles. 
Table 3 shows the tolerance to postoperative 
chemotherapy. Figure 1 shows the reasons why 
postoperative protocol chemotherapy was not started in 
the remaining patients. 
As of March 2007, the median follow-up was 3·9 years. 
We recorded 254 events of progression-free survival (the 
Preoperative 
chemotherapy 
(N=171)
Postoperative 
chemotherapy 
(N=115)
Administration of chemotherapy
Number of cycles
1 6 (4%) 7 (6%)
2 1 (1%) 10 (9%)
3 8 (5%) 5 (4%)
4 7 (4%) 5 (4%)
5 6 (4%) 8 (7%)
6 143 (84%) 80 (70%)*
Median (range) 6 (1–6) 6 (1–8)
Relative dose intensity
5-ﬂ uorouracil (%) 92·3% (50·0 to 111·3) 82·0% (36·9 to 112·2)
Oxaliplatin (%) 92·1% (54·6 to 106·0) 79·1% (0·0 to 106·5)
Dose reduction(s) 58 (34%) 69 (60%)
Delayed cycle(s) 75 (44%) 73 (64%)
Response to preoperative chemotherapy (RECIST)†
Complete response 4 (3%) ..
Partial response 63 (40%) ..
Stable disease 60 (38%) ..
Progressive disease 11 (7%) ..
After 3–4 cycles 7‡ (64%) ..
After 6 cycles 4§ (36%) ..
Not assessable 21 (13%) ..
Ineligible 5 (24%) ..
Benign lesion 2 (10%) ..
<3 cycles 10 (48%) ..
No follow-up 
measurements
4 (19%) ..
Sum of the largest diameters of lesions on imaging
At entry (mm) 50 (20 to 255) ..
After preoperative 
chemotherapy (mm)
33 (0 to 230) ..
Relative reduction (%) –25·6% (–100 to 228·6) ..
Data are number (%) or median (range). RECIST=response criteria in solid 
tumours.13 *Including one patient who received seven cycles and one who received 
eight cycles. †Assessed in patients with at least one baseline lesion 20 mm or more 
(N=159). ‡Three of seven patients underwent resection, one further patient who is 
not eligible for RECIST response assessment progressed after three cycles and did 
not undergo resection. §One of four patients underwent resection.
Table 2: Compliance, treatment tolerance, and treatment response to 
perioperative chemotherapy
PeriOpCT group Surgery group
Tolerance to preoperative chemotherapy (N=171)
Allergy grade 3* 1 (1%) ..
Diarrhoea grade 3* 14 (8%) ..
Nausea grade 3* 6 (4%) ..
Vomiting
Grade 3 4 (3%) ..
Grade 4 1 (1%) ..
Stomatitis/pharyngitis grade 3* 11 (7%) ..
Hand-foot skin syndrome grade 3* 0 ..
Sensory neuropathy grade 3* 4 (2%) ..
Cholinergic syndrome grade 3* 1 (1%) ..
Dysaesthesia grade 3* 4 (2%) ..
Other neurological toxicity grade 3* 10 (6%) ..
Hepatic grade 3* 5 (3%) ..
Cardiovascular grade 3* 4 (2%) ..
Febrile neutropenia  
Grade 3 1 (1%) ..
Grade 4 1 (1%) ..
Infection grade 3* 5 (3%) ..
Catheter-related infection grade 3* 0 ..
Leucopenia
Grade 3 9 (5%) ..
Grade 4 1 (1%) ..
Neutropenia
Grade 3 19 (11%) ..
Grade 4 12 (7%) ..
Thrombocytopenia grade 3* 2 (1%)
Haemoglobin grade 3* 1 (1%) ..
Postoperative complications
Number in group 159 170
Reversible postoperative complications† 40 (25%) 27 (16%)
Cardio-pulmonary failure 3 (2%) 2 (1%)
Bleeding 3 (2%) 3 (2%)
Biliary ﬁ stula 13 (8%) 7 (4%)
Output >100 mL/day for >10 days 9 (6%) 2 (1%)
Hepatic failure 11 (7%) 8 (5%)
Bilirubin >100 mg/day for >3 days 10 (6%) 5 (3%)
Wound infection 5 (3%) 4 (2%)
Intra-abdominal infection 11 (7%) 4 (2%)
Need for reoperation 5 (3%) 3 (2%)
Urinary infection 4 (3%) 0
Pleural eﬀ usion 3 (2%) 1 (1%)
Pulmonary embolism/deep-venous 
thrombosis
2 (1%) 1 (1%)
Pneumopathy 2 (1%) 0
Neutropenia 2 (1%) 0
Ascites 1 (1%) 1 (1%)
Ileus 2 (1%) 1 (1%)
Cardiac arrhythmia 0 1 (1%)
Renal failure 0 1 (1%)
Other 4 (3%) 4 (2%)
Postoperative death 1 (1%) 2 (1%)
(Continues on next page)
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primary endpoint) in all randomised patients (ﬁ gure 1), 
including 240 events in eligible patients. 22 patients 
assigned to chemotherapy and 19 to surgery were alive 
without disease and had been followed up for less than 
3 years. A total of 139 patients have died (ﬁ gure 1).
The HR for progression-free survival was 0·79 (95·66% 
CI 0·62–1·02; p=0·058) in all randomly assigned patients 
corresponding to a 7·3% increase in the rate of 
progression-free survival at 3 years from 28·1% 
(21·3–35·3) to 35·4% (28·1–42·7) with chemotherapy 
and to an increase of the median progression-free survival 
from 11·7 months to 18·7 months (ﬁ gure 2). An analysis 
of only patients who were eligible to enter the trial 
showed an HR of 0·77 (0·60–1·00, p=0·041), 
corresponding to an 8·1% increase in the rate of 
progression-free survival at 3 years from 28·1% 
(21·2–36·6) to 36·2% (28·7–43·8) with chemotherapy 
(ﬁ gure 2). In the 303 patients in whom resection was 
actually achieved after study entry, the analysis showed 
that the HR was 0·73 (0·55–0·97, p=0·025) and the rate 
of progression-free survival at 3 years was increased 
by 9·2% from 33·2% (25·3–41·2) to 42·4% (34·0–50·5) 
(ﬁ gure 2).
When the usual deﬁ nition of progression-free survival 
was used to compare treatments in all 
364 randomised patients (ie, those not operated or not 
resected were not penalised as events until further 
disease progression or death), the HR was 0·76 
(0·59–0·98, p=0·023) corresponding to a 7·3% increase 
in the rate of progression-free survival at 3 years 
from 28·6% (21·7–35·8) to 37·9% (30·5–45·3) with 
chemotherapy. Adjustment of the primary analysis for 
the stratiﬁ cation factors (risk grouping and previous 
adjuvant chemotherapy) did not change the results 
(data not shown).
Discussion
We have shown that perioperative chemotherapy with 
FOLFOX4 reduced the risk of progression-free survival 
events at 3 years by a quarter in patients with resectable 
liver metastases. In all patients randomly assigned to 
study treatments, the study showed a trend favouring 
administration of chemotherapy, which was not signiﬁ cant 
when a correction was used for the diﬀ erent timings of 
surgery in the two treatment groups. In all eligible and all 
resected patients the beneﬁ t was statistically signiﬁ cant. 
Our results have shown that perioperative chemotherapy 
was compatible with major liver surgery. Operative 
mortality was less than 1% in both treatment groups, 
which is very low after this type of liver surgery in a 
multicentre study. Reversible complications of surgery 
PeriOpCT 
group
Surgery 
group
(Continued from previous page)
Tolerance to postoperative chemotherapy (N=115)
Allergy 
Grade 3 4 (4%) ..
Grade 4 1 (1%) ..
Diarrhoea grade 3* 6 (5%) ..
Nausea grade 3* 5 (4%) ..
Vomiting grade 3* 3 (3%) ..
Stomatitis/pharyngitis grade 3* 0 ..
Hand-foot skin syndrom grade 3* 1 (1%) ..
Sensory neuropathy grade 3* 11 (10%) ..
Cholinergic syndrome grade 3* 1 (1%) ..
Dysaesthesia grade 3* 5 (4%) ..
Other neurological toxicity grade 3* 14 (12%) ..
Hepatic grade 3* 6 (5%) ..
Cardiovascular grade 3* 1 (1%) ..
Febrile neutropenia grade 3* 4 (4%) ..
Infection grade 3* 2 (2%) ..
Catheter-related infection grade 3* 5 (4%) ..
Leucopenia grade 3* 14 (12%) ..
Neutropenia
Grade 3 32 (28%) ..
Grade 4 8 (7%) ..
Thrombocytopenia grade 3* 8 (7%) ..
Haemoglobin grade 3* 1 (1%)
Data are n (%) unless otherwise stated. Patients may have several complications, 
therefore number of complications does not add up to the total number of 
patients. Common toxicity criteria10 version 2.0 was used. PeriOpCT=perioperative 
chemotherapy with ﬂ uorouracil or leucovorin and oxaliplatin *No grade 4 reported. 
†p=0·04. 
Table 3: Adverse events during chemotherapy and postoperative 
complications
PeriOpCT group 
(N=182)
Surgery group 
(N=182)
Operated 159 (87%) 170 (93%)
Resected 151 (83%) 152 (84%)
Monosegmentectomy 
or wedge resection
31 (20%) 33 (22%)
Plurisegmentectomy* 86 (57%) 81 (53%)
Multiple resections 33 (22%) 36 (24%)
Unknown 1 (1%) 2 (1%)
Not resected 8 (4%) 18 (10%)
More extensive disease 7 (88%) 18 (100%)
Liver damage 1 (13%) 0
Not operated 22 (12%) 8 (4%)
More advanced disease 10 (45%) 7 (88%)
Refusal 4 (18%) 0
Poor condition/death 3 (14%) 0
Other reason 5 (23%) 1 (13%)
Unknown 1 (1%) 4 (2%)
Time to surgery (weeks) 16·6 (0·1–30) 2 (0·1–16)
Data are number (%) or median (range). *Major resection, two or more segments. 
PeriOpCT=perioperative chemotherapy with ﬂ uorouracil or leucovorin and 
oxaliplatin.
Table 4: Patients who received surgery and resection
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were more frequent in patients who had received 
preoperative chemotherapy than in those who had received 
surgery alone, but remained within the range commonly 
noted after resection of liver metastases.1,3,18
In patients with advanced colorectal cancer, several 
studies have compared various chemotherapy regimens. 
However, very few prospective studies have investigated 
the combination of chemotherapy with surgery, and none 
has assessed perioperative chemotherapy. Most trials did 
not achieve the planned recruitment for multifactorial 
reasons (table 5).5–9 Although no level I evidence for a 
beneﬁ t of combining chemotherapy and surgery was 
reported, individual opinions in favour of one or the 
other treatment option prevented some oncologists and 
surgeons from including patients in trials. This trial met 
its target accrual, thanks to an intercontinental 
collaboration involving Europe, Australia, and Hong 
Kong. Any future trial of this type is unlikely to have a 
surgery-only group.19
The primary objective of this trial was to assess 
perioperative chemotherapy in patients qualifying for 
resection of their metastatic disease. Had we assessed 
postoperative chemotherapy only, randomisation could 
have been done after successful resection of the 
metastases, and no patient would have been excluded 
because of ineligibility or unresectability. Because of the 
speciﬁ c objective in our trial, patients had to be randomly 
assigned imperatively before surgery—ie, without any 
certainty that metastases assessed by imaging were 
actually resectable. This uncertainty represents a 
fundamental diﬃ  culty for all studies assessing 
preoperative treatment and makes such studies diﬃ  cult 
to undertake and analyse. For example, in the MAGIC 
(Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy) trial13 that assessed perioperative 
chemotherapy in gastric cancer, many randomised 
patients did not undergo complete resection of the 
cancer. In our trial, some metastases that were initially 
considered to be resectable at randomisation were 
actually more advanced and not resectable at surgical 
examination. Therefore we examined not only all 
randomised and eligible patients, but also those who 
received resection. All analyses were done according to 
the allocated treatment group (ie, including the patients 
who did not receive the allocated treatment). The number 
of patients who ﬁ nally underwent resection was much 
the same in both treatment groups.
The principal reason for non-resectability was more 
advanced disease than was expected, which was probably 
mostly due to a discrepancy between imaging and 
surgical examination. However, we noted a trend towards 
fewer failures to resect in the perioperative chemotherapy 
group than in the surgery group because of extensive 
disease, and a higher rate of failures to resect because of 
refusal or poor condition of the patient, which could 
introduce a selection bias. Results of progression-free 
survival in resected patients might be of interest in view 
Figure 2: Progression-free survival by treatment group
(A) All randomly assigned patients. (B) All eligible patients. (C) All resected patients. For all patients randomly 
assigned and those who were eligible, no surgery or no resection were regarded as events for the primary endpoint 
of progression-free survival. PeriOpCT=perioperative chemotherapy with ﬂ uorouracil or leucovorin, and oxaliplatin.
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of all other trials in this specialty, which assess 
postoperative chemotherapy only in patients with 
resected liver metastases since randomisation is done 
after surgery.5–9 Progress in imaging techniques (with 
spiral CT scan, MRI, PET scan, and contrast ultrasound) 
has further reduced the gap between imaging and surgery 
exploration when the resectability of liver metastases is 
assessed.20
In accordance with the statistical design in the protocol, 
unresected patients in both groups were counted as events 
for the primary endpoint of progression-free survival, 
which inevitably results in a dilution of the observed 
treatment diﬀ erence in all analyses including the unresected 
patients. The protocol considered all events of non-resection 
to have occurred at week 10 to not bias results because of 
the diﬀ erent timing of surgery in the two groups.
In this study, metastases progressed during preoperative 
chemotherapy in 12 patients (7%), four of whom were 
subsequently non-resectable because of the appearance 
of new lesions and four because of progression of already 
known metastases. In the four patients with new lesions, 
immediate surgery would not have been beneﬁ cial since 
new metastases would have appeared anyway. In the four 
patients with progression of the known metastases, 
resection would also probably have been followed by 
progression.21 Progression during preoperative chemo-
therapy should rather be regarded as a biological marker 
for poor prognosis and an indication for administra-
tion of second-line chemotherapy before surgery is 
considered.
Chemotherapy does induce liver damage which varies 
according to the drugs given. Vascular lesions, but no 
steatohepatitis, have been noted after administration of 
oxaliplatin.22–24 Whether these liver lesions might aﬀ ect 
the safety of subsequent surgery and thus counterbalance 
the potential beneﬁ ts of treatment is unknown. Karoui 
and colleagues25 showed that the risk of surgical 
complications after preoperative chemotherapy is related 
to the number of chemotherapy cycles, and that this risk 
remains low if not more than six cycles are given 
preoperatively. We administered only six cycles 
preoperatively. The mortality rate was very low. The 
complication rate was higher in the chemotherapy group 
than in the surgery group but was similar to other series 
of patients undergoing hepatectomy.1,3,18 These 
complications were reversible. We believe that this 
moderate increase in the risks of liver surgery after 
chemotherapy does not compromise the potential 
beneﬁ ts of the treatment.
In this study, chemotherapy was given before and after 
surgery. Previous trials5–9 showed a trend towards a 
beneﬁ t of postoperative-only chemotherapy; however, 
our trial was not designed to compare preoperative and 
postoperative chemotherapy. The improvement in 
progression-free survival with chemotherapy was 
recorded during the ﬁ rst 2 years but afterwards the curves 
seemed to remain parallel. Similarly, the MAGIC trial 
showed that perioperative chemotherapy increases 
overall survival, whereas most trials of postoperative 
chemotherapy alone did not show a beneﬁ t.13,26
This trial was restricted to patients with four or fewer 
metastases to reduce the proportion of patients that 
would be entered and later found to have more 
metastases than were detected on imaging, some of 
which would be unresectable. This restriction was not 
intended to serve as a deﬁ nition of unresectability, but to 
serve as a selection criterion for the trial. These patients 
with a few metastases are those with best prognosis after 
surgical resection. We believe that the conclusions from 
this trial would probably also be valid for patients at 
higher risk. Future trials could thus investigate the 
potential beneﬁ t of intensiﬁ ed perioperative chemo-
therapy in resectable liver metastases from colorectal 
cancer. The combination of targeted agents with cytotoxic 
therapy has shown high response rates27–29 and thus 
warrants assessment in the perioperative setting. At 
present the EORTC 40051 BOS (Biologics, Oxaliplatin 
and Surgery) trial30 is assessing perioperative 
chemotherapy with FOLFOX6 and cetuximab with or 
without bevacizumab in patients with resectable hepatic 
metastases from colorectal cancer.
We conclude that perioperative FOLFOX4 chemotherapy 
reduced the risk of events of progression-free survival by 
a quarter and was compatible with major surgery. In all 
randomised patients the study showed a trend favouring 
administration of chemotherapy. In all eligible and in all 
resected patients, the beneﬁ t of administering 
chemotherapy was signiﬁ cant.
Number of resected 
metastases 
Median follow-up 
(months)
Number of 
patients
Randomised postoperative treatments Median TTP/PFS (months) Median overall 
survival (months)
Lorenz M (1998)5 ≤6  liver metastases ≥18 108 vs 111 HAI FU/FA vs surgery alone 14·2 vs 13·7 (NS) 34·5 vs 40·8 (p=0·15)
Kemeny N (1999)6 Any number of liver metastases 62·7 74 vs 82 Systemic FU/FA+HAI  FUDR vs systemic FU/FA 37·4 vs 17·2 (p=0·06) 72·2 vs 59·3 (p=0·21)
Kemeny M (2002)7 1–3 liver metastases 51 30 vs 45 HAI FUDR+systemic FU vs surgery alone 45·7%* vs 25·2%* (p=0·04) 63·7 vs 49·0 (p=0·60)
Mitry E (2006)8 ≤4 liver or lung metastases NR 138 vs 140 Systemic FU/FA vs surgery alone 26·4 vs 18·6 (p=0·059) 61·1 vs 46·9 (p=0·125)
Portier G (2006)9 Any number of liver metastases 87 86 vs 87 Systemic FU/FA vs surgery alone 24·4 vs 17·6 (p=0·028) 62·1 vs 46·4 (p=0·13)
TTP=time to progression. PFS=progression-free survival. HAI=hepatic arterial infusion. FUDR=ﬂ oxuridine. FU=ﬂ uorouracil. FA=folinic acid. NS=not signiﬁ cant. NR=not reported. *4-year progression-free 
survival rates.
Table 5: Previous studies of adjuvant chemotherapy in patients with resected liver metastases from colorectal cancer
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